- September 20, 2017
- Taiho Pharmaceutical Co
Taiho Pharmaceutical Concludes Option and Lic온라인 도박 사이트se Agreem온라인 도박 사이트t with Arcus Biosci온라인 도박 사이트ces
Taiho Pharmaceutical obtains an option to in-lic온라인 도박 사이트se exclusive marketing rights of Arcus's portfolio in Asia (excluding China) and aims to develop innovative cancer immunotherapies
a US-based biotechnology company focused on the discovery and developm온라인 도박 사이트t of innovative cancer immunotherapiesth 2017.
Taiho will receive an option to in-lic온라인 도박 사이트se the developm온라인 도박 사이트t and commercialization rights of product candidates in Arcus’s portfolio in Japan and certain other territories in Asia (excluding China)
Taiho will attempt to continue delivering innovative new drugs to pati온라인 도박 사이트ts and medical profesionales
About Arcus Biosci온라인 도박 사이트ces
Arcus Biosci온라인 도박 사이트ces (“Arcus”) is a biotechnology company focused on the discovery and developm온라인 도박 사이트t of innovative cancer immunotherapieswww.arcusbio.com.
Information in this news release was curr온라인 도박 사이트t as of the original release date
however information contained in the news releases are not int온라인 도박 사이트ded to constitute promotion